Latest Kaiser Health News Stories
From Medicare dental coverage to drug prices to fetal tissue research, the panelists answer listeners’ questions. Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Paige Winfield Cunningham of The Washington Post join KHN’s Julie Rovner.
California’s incoming congressional delegation will be the largest in the U.S. House of Representatives to support progressive health care policies such as “Medicare-for-all.” But the political reality of a Republican Senate and president means that they will need to pursue ideas that “aren’t pie in the sky.”
The fallout continues from that Texas court decision that ruled Congress’ 2017 elimination of the tax penalty for failing to have insurance rendered the entire Affordable Care Act unconstitutional. Meanwhile, enrollment for 2019 at healthcare.gov was down, but far less than many predicted. KHN’s Julie Rovner, along with panelists Joanne Kenen of Politico, Anna Edney of Bloomberg News and Kimberly Leonard of the Washington Examiner, discuss this, plus the best, most overhyped and nerdiest stories of 2018. Also, Rovner interviews GOP strategist and pollster Frank Luntz.
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
Medicare instructs inspectors to look for staffing inadequacies in homes that report suspiciously low numbers of registered nurses and weekend workers.
The federal government is issuing bonuses and penalties to skilled nursing facilities based on how often their patients are readmitted to hospitals within a month of being discharged.
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”
Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Joanne Kenen of Politico and Anna Edney of Bloomberg News discuss the latest on open enrollment for the Affordable Care Act and Medicare; new moves by the Food and Drug Administration to regulate tobacco and nicotine products; and whether House Democrats will pursue a “Medicare-for-all” bill in the next Congress. Plus, for extra credit, the panelists recommend their favorite health policy books for your holiday reading and gifting pleasure.
Federal officials are hailing the introduction of services such as transportation to medical appointments, home-delivered meals and installation of wheelchair ramps as a way to keep beneficiaries healthy and avoid costly hospitalizations. But not many plans are offering the services in 2019.
Even though they are taking control of the House, Democrats will be unlikely to advance many initiatives on health that don’t meet Republican approval since the GOP controls the Senate and the White House. But they can block any efforts to weaken the Affordable Care Act or change Medicaid or Medicare.
KHN’s news analysis on “Medicare-for-all” sparks a broader conversation.
A number of health issues — from preexisting conditions to Medicaid expansion to changes to Medicare — could be at stake when voters head to the polls Tuesday.
Republicans seek to turn the tables on charges that they are undermining preexisting conditions, so they’re hammering the plans championed by some Democrats to expand Medicare.
Although dialysis provider DaVita Inc. has taken major financial hits this year, including a $383.5 million jury award in response to wrongful death lawsuits, it still rakes in profits. The company faces its biggest threat next month, when California voters weigh in on a ballot initiative that could force it to leave the state.
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.